Zhi-xiang Cheng

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

P. Liu, Jing Li, Zheng Wei, 2017, Journal of thoracic disease.

HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China

Junmin Li, Yunfeng Cheng, Zheng Wei, 2014, Medical Oncology.

The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides

P. Liu, Tianhong Xu, Jing Li, 2020, Leukemia & lymphoma.

Histological Impact on Follicular Lymphoma Grade 3 Treated With Frontline RCHOP Regimen

Peng Liu, Lijuan Yuan, Zheng Wei, 2021 .

A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients

Peng Liu, Tianhong Xu, Lijuan Yuan, 2023, Clinical and experimental medicine.

Real World Data on the Efficacy and Safety of Ixazomib Based Therapy in Multiple Myeloma: An Observational Study from China

Jing Li, Zheng Wei, Peng Liu, 2019, Clinical Lymphoma Myeloma and Leukemia.